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Objectives: To evaluate, by means of a
prospective randomized study, the effica-
cy of cinacalcet in the forms of nephrolithiasis associated
with primary hyperparathyroidism in both the hypercal-
cemic and normocalcemic variant.
Materials and Methods: Ten patients suffering from active
nephrolithiasis associated with primary hyperparathy-
roidism (4 hypercalcemics and 6 normocalcemics), equally
divided between males and females, were randomly but
not blindly addressed to treatment with potassium citrate
and allopurinol, or to the same therapeutic regimen in
combination with cinacalcet. The dosage of cinacalcet was
optimized for each patient in order to obtain a reduction
of parathyroid hormone (PTH) within normal limits while
enabling the maintenance of adequate calcemic values. All
study participants were given the same diet based on a
reduction in sodium intake, oxalate-rich foods and animal
protein with standardized intake of calcium and an
increase in hydration. After a follow up period of 10
months , cinacalcet was associated to standard therapy
and diet in patients who were not taken it, conversely
cinacalcet was withdrawn in the remaining patients who
remained on standard therapeutic regimen and diet.
Follow up was continued for a second period of observa-
tion of the same duration of the first. 
Results: At the end of the period of treatment with cinacal-
cet, for both variants of hyperparathyroidism, a statisti-
cally significant reduction in the overall number and in
the diameter of renal stones was found.
Conclusions: This prospective randomized study shows the
effectiveness of cinacalcet used in combination with a diet
with normalized calcium intake, in reducing the number
and size of urinary stones in hypercalemic and normocal-
cemic forms of primary hyperparathyroidism.
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INTRODUCTION
Primary hyperparathyroidism is a disease characterized by
elevated levels of parathyroid hormone (PTH) that in 70-
80% of cases is caused by isolated parathyroid adenoma
and in the remaining from a diffuse hyperplasia of all
glands (1). Primary hyperparathyroidism is one of the
most common endocrine disorders and classically pres-
ents with hypercalcemia, nephrolithiasis and reduced
bone mass (2). Since last decade it has also been described
a new clinical form of primary HPT, defined normocal-
cemic primary hyperparathyroidism, characterized by
total and ionized calcium concentrations within the nor-
mal limits even in the presence of a constant elevation of
the levels of PTH and in the absence of alterations that
may justify a secondary elevation of PTH (3). Diagnosis of
primary hyperparathyroidism implies absence of second-
ary causes of elevation of PTH such as 25-hydroxyvitamin
D deficiency, decreased creatinine clearance, use of drugs
such as hydrochlorothiazide and lithium salts, idiopathic
hypercalciuria, gastrointestinal disorders associated with
malabsorption syndromes (3). Nephrolithiasis is present
in 15-20% of patients with hypercalcemic primary hyper-
parathyroidism (4) but also normocalcemic primary
hyperparathyroidism is associated with such an high
prevalence of nephrolithiasis (18.2% according to Amaral
et al.)(2). Similar incidences were demonstrated for bone
fractures (2). Most stones found in patients with primary
hyperparathyroidism are composed of calcium oxalate
and, in case of alkaline urine, of calcium phosphate (5). In
this context, hypercalciuria (due to the fact that the
increase of filtered calcium related to hypercalcemia com-
pensates and even surpasses distal tubular reabsorption of
calcium directly induced by parathyroid hormone) is a
predisposing factor for stone formation (6). However it is
not clear why some patients with primary hyperparathy-
roidism, both normocalcemic or hypercalcemic, tend to
form stones and others do not. In fact, in studies that
aimed at comparing the biochemical profile of patients
with hyperparathyroidism with or without associated
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nephrolithiasis (7, 8) hypercalciuria was found in only
39% of the patients with hyperparathyroidism and only
29% of those with hypercalciuria had nephrolithiasis (9).
On the other hand, the urinary excretion of calcium not
necessarily differentiates patients with and without kidney
stones because urinary excretion of calcium is only one of
at least six factors that can cause urinary supersaturation
of calcium salts leading to the formation of kidney stones.
For this reason very high levels of urinary calcium excre-
tion are no longer considered an indication for parathy-
roidectomy (9, 10). Regarding the clinical management of
the two forms of primary hyperparathyroidism while there
are clear indications about the hypercalcemic classical
form, where a relapsing form of nephrolithiasis is consid-
ered a clear indication to parathyroidectomy (10, 11), for
the normocalcemic form there are currently insufficient
data to recommend parathyroidectomy or just observation
(12). On the other hand, also in some classical form of
hypercalcemic hyperparathyroidism, when parathyroidec-
tomy has not a sure indication or is not feasible or is
refused by the patient, there is an option for adequate
monitoring and prevention measures such as hydration
and a dietary regimen with normalized calcium intake
similarly to that recommended in the general population
or for the use of specific drugs (1). Pharmacological ther-
apy consists mainly of bisphosphonates, which inhibit
bone resorption and can increase bone density while low-
ering the blood concentration and urinary excretion of cal-
cium (1) and calcimimetics, such as cinacalcet, which act
as activators of the calcium-sensing receptor at level of
both the parathyroid and the kidney and are capable of
inducing a suppression of parathyroid secretion and thus
reducing serum calcium levels, while increasing serum
phosphorus (1, 13). Cinacalcet can be used to normalize
the serum calcium in patients with symptomatic hypercal-
cemia that they cannot be submitted to parathyroidecto-
my, particularly if bone density is normal, because this
drug is not able to reduce the bone turn-over or to
increase bone mineral density (13, 14). However, effects
of cinacalcet on calciuria are not well known and in fact in
a study of Peacock et al. (14) urinary calcium was reduced
in treated patients both in the first morning urine and in
24 hour urine, but this difference appeared statistically
significant only for first morning urine. It is likely that the
basis of such behavior is the complexity of the mechanism
of action of cinacalcet that on one hand determines an
increase in of calcium excretion but on the other hand
reduces the levels of serum calcium and the filtered load
of calcium (1). The finding of reduced urinary calcium in
the early morning urine in absence of a reduction of calci-
um excretion in the 24-hour urine may be explained by
the fact that the 24-hour urinary calcium reflects a com-
ponent linked to intestinal absorption of calcium that
appears to be increased in patients with hyperparathy-
roidism forming stones (15). To date, however, there is no
data in the literature on what may be the consequence (in
terms of change in the number and size of stones) arising
from the use of cinacalcet in the forms of nephrolithiasis
associated with both hypercalcemic and normocalcemic
primary hyperparathyroidism (1, 11) The present pilot
study was therefore intended to investigate possible direct
effects on renal stone formation with the use of cinacalcet
in the forms of nephrolithiasis associated with both hyper-
calcemic and normocalcemic primary hyperparathy-
roidism.
MATERIALS AND METHODS
Study design 
To evaluate the therapeutic effects of cinacalcet in
patients with active nephrolithiasis associated with pri-
mary hyperparathyroidism were enrolled 10 patients
equally divided between males (mean age 55.6 ± 8.3
years) and females (mean age 62.4 ± 11 8 years, all post-
menopausal except one). Four patients, equally divided
between males and females, were affected by the hyper-
calcemic variant of primary hyperparathyroidism and
the other six, which are also equally divided between
males and females, were instead affected by thenormo-
calcemic variant of hyperparathyroidism (Table 1).
Criteria for inclusion and exclusion 
Patients were considered eligible for the study if they had
a documented active form of kidney stone disease (2 or
more stones formed during the previous two years) associ-
ated to both hypercalcemic or normocalcemic primary
hyperparathyroidism characterized by intact PTH levels, as
determined by the method Immunoassay, consistently
high (> 79.6 pg/ml). We excluded patients with known
causes of secondary elevation of parathyroid hormone
such as 25-hydroxyvitamin D deficiency (defined as serum
25-hydroxyvitamin D less than 20 ng/ml) (16), decreased
creatinine clearance (defined as the finding of a GFR less
than 50 ml/min) (14), use of drugs such as hydrochloroth-
iazide and lithium salts, gastrointestinal disorders associat-
ed to malabsorption of calcium and idiopathic hypercalci-
uria (defined as the presence of urinary calcium > 300
mg/24 h in men and 250 mg/24 h in women or urinary
calcium levels in 24 hour urine greater than 4 mg/kg body
weight for both sexes in the absence of known causes of
hypercalciuria such as sarcoidosis, rapidly progressive
osteoporosis, excessive intake of vitamin D or calcium,
immobilization, hyperthyroidism, renal tubular acidosis
and the presence of any neoplasm) (17). In this regard, we
specify that in the study were also enrolled two patients
(one male suffering from the hypercalcemic variant of
hyperparathyroidism and a female affected by the normo-
calcemic variant hyperparathyroidism) with higher values
of urinary calcium (> 4 mg/kg body weight). In order to
exclude an elevation of PTH secondary to hypercalciuria,
before starting the study, we treated these patients for three
months with a thiazide diuretic such as hydrochloroth-
iazide at a dose of 12.5 mg bis in die, according to Coe et
al. (17), and we were able to observe that despite the
reduction of urinary calcium within normal limits, there
was no decrease of parathyroid hormone that was further
increased in association with an increase of serum calcium.
On this basis we assumed that in such patients, as well as
in at least another case already described in the study of
Coe et al. (17), hypercalciuria was not the cause of the ele-
vation of PTH thet was rather primitive and independent
of the levels of calciuria since it remained unchanged in
spite of the correction of hypercalciuria. Such patients after
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a wash out period without thiazide were then enrolled in
the study. Finally, the normocalcemic forms were defined
by the presence of values of total serum calcium (correct-
ed for albumin) within normal limits with respect to the
laboratory reference range used (8.4 to 10.6 mg/dl) and
hypercalcemic forms were defined after at least two con-
secutive determinations consistently high (18).
Study protocol 
Written informed consent was required to all patients at
the time of enrollment. At baseline, all patients maintained
their usual meals and were subjected to a screening labo-
ratory including the blood determination of urea nitrogen,
creatinine, sodium, potassium, calcium, phosphorus, uric
acid, total protein, protein electrophoresis, 25 hydroxy
vitamin D and parathyroid hormone while in the 24-hour
urine were measured creatinine, citrate, uric acid, calcium,
phosphate, oxalate and magnesium, calcium/creatinine
ratio and volume. In first morning urine was measured pH
and were performed urine culture and Brand test to
exclude infectious forms or cystinuria. Glomerular filtra-
tion rate was then calculated with CKD EPI formula (19).
Renal ultrasound was performed to evaluate presence,
number and larger diameters of stones and to exclude
hydronephrosis. Each patient was also subjected to med-
ical examination with determination of weight, height and
arterial blood pressure. The same blood and urine tests
(except for the test of Brand) and ultrasound examination
of the urinary tract were repeated at the end of each of the
successive periods of observation, when the patients were
again subjected to medical examination with recording of
weight, blood pressure and data related to compliance
with therapy and diet and any adverse reaction to the treat-
ment. Since this was a case control study in which patients
were controls of themselves, the subjects enrolled were
directed to a first observation period of 10 months, during
which were assigned to standard treatment with potassium
citrate at a dose of 50 mEq daily and/or allopurinol at a
dose of 300 mg daily, when required by alterations
emerged from the metabolic study. This regimen was asso-
ciated at random but not blindly to cinacalcet administra-
tion. The dosage of cinacalcet was optimized for each indi-
vidual patient to obtain a reduction of PTH within normal
limits while enabling the maintenance of adequate values
of calcemia. At the end of the first observation period,
cinacalcet therapy was added, for a second period of obser-
vation of the same length as the first, in patients who were
not taking it, or withdrawn in patients who were assuming
it in the first period. Finally, in all patients, at the time of
the basal visit was prescribed an equal dietary regimen
based on a reduction of sodium intake, foods rich in
oxalate and protein of animal origin, with normalized
intake of calcium (0, 8-1 g daily) and increase in hydration
(> 2 liters daily) by use of mineral waters with moderate
calcium content (20). This dietary regimen is ideal for the
prevention and the contrast of nephrolithiasis even when
it is associated to a form of primary hyperparathyroidism.
On the contrary low calcium diet was avoided because it
exposes the patient to the risk of osteopenia and has an
adverse effect on the risk of stone formation because of the
increase of oxalate excretion due to increased intestinal
absorption of calcium (1). The parameters used to evaluate
the efficacy of therapeutic regimens and dietary regimen
during each of the two observation periods were the dif-
ferential variations of the above mentioned blood and uri-
nary parameters as well as differential changes in the over-
all number of urinary calculi and the larger diameter of the
stones. To accurately quantify the differential changes in
the number of stones, spontaneous stone passages were
also recorded, as evidence of the formation of new stones
, in the absence of the detection of stones at the time of the
entry in the study, as well as stone passages without
changes in the total number of stones at the final ultra-
sound examination and also episodes of stone treatment
with shock wave lithotripsy and/or surgical removal of
stones during the follow-up period. 
Data collection and statistical analysis
All determinations were carried out at the Laboratory of
Analysis of the S. Donato of Arezzo using Siemens kit for
citraturia, uricosuria and oxaluria based on enzymatic
methods and Siemens kit for urinary calcium, phospha-
turia and magnesuria based on colorimetric methods.
Determination of intact parathyroid hormone was
instead performed by enzyme immunoassay (Tosoh AIA
900). Descriptive statistics (means and standard devia-
tion) for overall patients and group of patients were
obtained. Statistical comparisons for any significant dif-
ference between sexes, observation periods and sub-
groups with hypercalcemic and normocalcemic variant
of hyperparathyroidism were performed. Data distribu-
tions were normal to the Kolmogorov-Smirnov test and
Student t test was used for significant differences
between the means of samples. The parametric t test has
high power and is therefore able to reveal significant dif-
ferences also with reduced samples, such as those of the
study in question. For multiple paired comparisons the
Bonferroni correction was applied to at the level of sta-
tistical significance equal to 95% (p < 0.05).
RESULTS
All patients completed the two scheduled observation peri-
ods, no one was excluded because of intolerance or lack of
compliance and during both observation periods no spon-
taneous expulsion of stones or fragments was recorded nor
was necessary to practice any lithotripsy treatment and /or
surgical procedure for removal of urinary calculi. 
Effect of cinacalcet and other therapies 
and dietary recommendations on stone formation
At the end of the observation period with cinacalcet a sta-
tistically significant reduction in the total number of
stones in comparison with the total number at the end of
the observation period without cinacalcet (number of
stones at the end of the observation period without
cinacalcet 3.2 ± 2.5 versus number of stones at the end of
the period of observation with cinacalcet 2.3 ± 2.8;
p = 0.019) and with the total number at enrollment (num-
ber of stones at enrollment: 3 ± 2.5 units vs. number of
stones at the end of the observation period with cinacalcet
2.3 ± 2.8 units; p = 0.045) was found, while there was no
change between this figure at enrollment and the one
recorded at the end of the observation period without
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cinacalcet. At the end of the observation period with
cinacalcet It was also found a statistically significant
reduction of the larger diameter of stone in comparison
with the period of observation without cinacalcet (diame-
ter of larger stone at the end of observation period with-
out cinacalcet: 0.78 ± 0.36 cm versus larger diameter of
stone at the end of the observation period with cinacalcet:
0.47 ± 0.38 cm; p = 0.000) and at enrollment (larger
diameter of stone at enrollment: 0.805 ± 0.21 cm versus
larger diameter of stone at the end of the observation peri-
od with cinacalcet: 0.47 ± 0.38 cm; p = 0.002), while no
there was no change between this figure at enrollment and
the one recorded at the end of the observation period
without cinacalcet (Table 2).
Effect of cinacalcet and other therapies and 
dietary recommendations on biochemical parameters 
At the same time, as expected, a statistically significant
reduction in serum calcium and parathyroid hormone was
recorded at the end of the observation period with cinacal-
cet in comparison with both the observation period with-
out cinacalcet (serum calcium at the end of the observa-
tion period without cinacalcet 10.2 ± 0.94 mg/dl versus
serum calcium at the end of the period observation with
cinacalcet: 8.9 ± 0.6 mg/dl; p = 0.000) (PTH at the end of
the period of observation without cinacalcet: 126.5 ± 73.3
pg/ml versus PTH at the end of the period of observation
with cinacalcet: 68.9 ± 38.7 pg/ml; p = 0.039) and at
enrollment (serum calcium at enrollment: 10 ± 0.8 mg/dl
versus serum calcium at the end of the observation period
with cinacalcet: 8.9 ± 0.6 mg/dl; p = 0.000) (PTH at
enrollment: 136.3 ± 72.5 p /ml versus PTH at the end of
the observation period with cinacalcet: 68.9 ± 38.7 pg/ml;
p = 0.016), while there was no variation between data at
enrollment and data recorded at the end of the observa-
tion period without cinacalcet. A statistically significant
increase of serum phosphorus and first morning urinary
pH was observed when data at enrollment and data
recorded at the end of the observation period with cinacal-
cet were compared (serum phosphorus at enrollment: 2.9
± 0.69 mg/dl versus phosphorus at the end of the obser-
vation period with cinacalcet: 3.6 ± 0.6 mg/dl; p =0.001),
(fasting urine pH at enrollment: 5.3 ± 0.47 versus fasting
urine pH at the end of the observation period with
cinacalcet: 6.5 ± 0.9; p = 0.039), whereas no change was
found in the comparison between data found at the end of
the observation period without cinacalcet and data at the
end of the observation period with cinacalcet and in the
comparison of data at enrollment and data at the end of
the period without cinacalcet.. 
Finally a statistically significant reduction of uric acid
excretion was found comparing data at enrollment and
data observed at the end of the observation periods with
and without cinacalcet (24-h urinary uric acid at enroll-
ment: 509.1 ± 165.4 mg/24 h versus 24-h urinary uric
acid at the end of the observation period without cinacal-
cet: 347 ± 118 mg/24 h; p = 0.024) (24-h urinary uric acid
at enrollment: 509.1 ± 165.4 mg/24 h versus 24-h urinary
uric acid at the end of the observation period with cinacal-
cet: 323 141 ± 6 mg/24 h; p= 0.031) whereas there was
no change between the data found at the end of the two
observation periods (Table 2). 
Comparison of hypercalcemic 
and normocalcemic hyperparathyroidism
As expected, higher mean values of serum calcium
(serum calcium at enrollment: 11 ± 0.16 mg/dl for the
hypercalcemic variant versus 9.3 ± 0.35 mg/dl for the
normocalcemic variant, p = 0.000; serum calcium at
the end of the observation period without cinacalcet:
11.2 ± 0.25 mg/dl for the hypercalcemic variant versus
9.5 ± 0.24 mg/dl for the normocalcemic variant, p =
0.000; serum calcium at the end of the observation
period with cinacalcet: 9 52 ± 0.35 mg/dl for the hyper-
calcemic variant versus 8.64 ± 0.50 mg/dl for the nor-
mocalcemic variant, p = 0.017) and lower mean values
of serum phosphate (serum phosphate at enrollment:
2.23 ± 0, 30 mg/dl for the hypercalcemic variant versus
3.4 ± 0.40 mg/dl for the normocalcemic variant, p =
0.005; serum phosphate at the end of the observation
period without cinacalcet 2.4 ± 0.50 mg/dl for the
hypercalcemic variant versus 3.6 ± 0.49 mg/dl for the
normocalcemic variant, p = 0.010; serum phosphate at
the end of the observation period with cinacalcet 3.1 ±
0.20 mg/dl for the hypercalcemic variant versus 3.97 ±
0.59 mg/dl for the normocalcemic variant, p = 0.025)
were observed in patients suffering from hypercalcemic
variant of hyperparathyroidism than in those affected
by the normocalcemic variant both at enrollment and at
the end of the observation period with and without
cinacalcet. 
Similarly higher mean PTH values in patients with the
hypercalcemic variant of hyperparathyroidism than in
those with the normocalcemic variant were found both
at enrollment and at the end of the observation period
without cinacalcet (PTH at enrollment 191 ± 87.4
pg/ml for the hypercalcemic variant versus 99.9 ± 29.9
pg/ml for the normocalcemic variant, p = 0.042; PTH at
the end of the observation period without cinacalcet
191.4 ± 80.5 pg/ml for the hypercalcemic variant ver-
sus 83.3 ± 13.6 pg/ml for the normocalcemic variant,
p = 0.011). 
Conversly, at the end of the observation period with
cinacalcet no statistically significant difference between
the mean values of PTH in the two variants of primary
hyperparathyroidism was observed. 
Finally, no statistically significant difference between
the two variants of hyperparathyroidism for all other
parameters taken into account, including the number
and size of the stones, was found (Table 3). 
Results of the t test for equality 
of means between females and males
T-test for equality of means between females and males
led to the identification of a statistically significant dif-
ference only for the larger stone diameter that was
greater in female subjects both at enrollment and at the
end of the observation period with cinacalcet (larger
diameter of stone at enrollment in female subjects:
0.94 ± 0.18 cm versus larger diameter of stone in
males: 0.67 ± 0.15 cm; p = 0.027; larger diameter of
stone at the end of the observation period with cinacal-
cet in female subjects: 0.71 ± 0.36 cm versus larger
diameter of the stone after of the observation period
with cinacalcet in males: 0.24 ± 0.24 cm; p = 0.038). 
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Adverse reactions of treatment 
No problem related to adverse reactions or intolerance
was reported in any of the two major therapeutic groups.
Tables posted in Supplementary Materials on
www.aiua.it
DISCUSSION
This study, with the limits of a pilot trial conducted on a
limited number of patients, shows, for the first time, the
ability of cinacalcet, used in combination with a dietary
regimen with a standardized intake of calcium, to reduce
in a statistically significant way the total number of renal
stones and the larger diameter of stones in patients with
nephrolithiasis associated with primary hyperparathy-
roidism both in the normocalcemic and hypercalcemic
variant. Our data also shows the ineffectiveness, within
the same period of comparison, of the traditional thera-
peutic and dietary approach. The aforementioned varia-
tions in the number and size of renal stones with the use
of cinacalcet resulted associated to changes in the
endocrine and metabolic parameters, as widely expected,
with a statistically significant reduction in serum calcium
and parathyroid hormone and a statistically significant
increase of serum phosphorus (PTH inhibits the tubular
reabsorption of phosphorus and thus increases its uri-
nary excretion) (21) and of urinary pH in the first morn-
ing urine (high levels of parathyroid hormone result in
an initial transient renal acidosis which is offset by an
increase in net acid excretion and the release of alkaline
bases of bone resorptive origin) (22). As for the compar-
ison between the two variants of hyperparathyroidism
(normocalcemic and hypercalcemic), we observed, as
expected, statistically significant higher values of serum
calcium and statistically significant lower phosphorus
values in patients with the hypercalcemic variant. Values
of parathyroid hormone were significantly higher in
patients with the hypercalcemic variant of hyperparathy-
roidism than in those affected by the normocalcemic
variant although this difference disappeared at the end of
the observation period cinacalcet Absence of statistically
significant difference between the mean values of
parathyroid hormone in the two variants of hyper-
parathyroidism is a finding directly related to the use of
cinacalcet at individually tailored dosages to achieve a
normal range for PTH. Precisely, with the use of cinacal-
cet at an optimized dose for each patient in order to
enable the achievement of values of parathyroid hor-
mone in the normal range, as described above, and to
mantain adequate values of calcemia, no statistically sig-
nificant difference between the two forms of hyper-
parathyroidism in the number and size of stones was
observed. Therefore, the above reported findings should
be explained by cinacalcet administered in association
with a diet standardized in calcium intake at a average
daily dose of 48.86 ± 30.09 mg titrated in each patient to
achieve values of parathormone within the normal range
and serum calcium levels as well within the limits of the
normal range. Obviously doses of cinacalcet were higher
(and mostly refracted in two daily doses) in subjects suf-
fering from the hypercalcemic variant of primary hyper-
parathyroidism (mean daily dose 63.75 ± 39.44 mg in
two doses in 75% of cases with the hypercalcemic vari-
ant versus 38.92 ± 20.02 in two doses in 50% of cases
with the variant normocalcemic variant). As mentioned
in the introduction, although a factor which contributes
to the formation of stones in primary hyperparathy-
roidism is hypercalciuria, the urinary excretion of calci-
um per gram of creatinine do not necessarily differenti-
ate patients who associate or not nephrolithiasis to pri-
mary hyperparathyroidism (7-9). Furthermore, although
a high concentration of serum calcitriol linked to stimu-
lation by PTH of renal hydroxylation of 25-hydroxyvita-
min D, can contribute both to hypercalciuria and the for-
mation of kidney stones, as shown in a study of 50
patients (23), this finding has to be confirmed because it
was not observed in another study carried out in an even
greater population (24). There are no differences in
serum parathyroid hormone, calcium or calcitriol in
patients with hyperparathyroidism with and without
associated nephrolithiasis, though hypercalciuria is more
often found in the group suffering from kidney stones (9,
25). This evidence is confirmed by the results of this
study clearly showing that cinacalcet used in combina-
tion with a diet with standardized calcium intake (and
not other treatment or dietary recommendations or the
combination of both) has induced a reduction in the
number and size of stones in association with a correc-
tion within normal limits of normality of parathyroid
hormone without changes of other metabolic parameters
taken into account (except for the increase of pH in the
first morning urine). Significant changes in urinary calci-
um induced by cinacalcet were not expected in consid-
eration of the mechanism of action of calcium mimetics
that act as allosteric activators of the receptors for calci-
um by increasing the sensitivity of these to calcium ions
(21). At renal tubular level the activation of the calcium-
sensitive receptors leads to a reduction in the absorption
of calcium and therefore to an increase in urinary calci-
um that appears counterbalanced however, in most
patients, by the simultaneous decrease of the levels of
PTH and serum calcium induced by the same treatment
with calcium mimetics (21). The fractional excretion of
calcium depends on the interaction between filtered load
and tubular reabsorption and cinacalcet acts on both
mechanisms, by reducing the first, through a reduction
in serum calcium, and the second with its action in the
distal tubular with a final net effect of substantially
unchanged (1). This was confirmed, by example, in the
study of Crockett et al. (26) where it was found that
cinacalcet normalized serum calcium and safely lowered
PTH without increasing the urinary excretion of calcium
in the study subjects and so proving the potential bene-
fit of this medical treatment for primary hyperparathy-
roidism. In the prospective study by Peacock et al. it was
also reported minimal change in urinary calcium in
patients treated with cinacalcet 30-60 mg daily, although
there was a statistically significant reduction in fasting
urinary calcium (14). Only patients carrying the poly-
morphism Arg990Gly of the calcium-sensitive receptor,
that leads to a permanent increase in the sensitivity of
these receptors, respond more strongly to cinacalcet, and
could be exposed to an increased risk of nephrolithiasis
during treatment with calcium mimetics (21). 
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CONCLUSIONS
It is not possible to draw other conclusions from our
study, in particular for the limited number of subjects
enrolled and the limited period of observation, other that
in subjects suffering from nephrolithiasis in association
with primary hyperparathyroidism (both normocal-
cemics and hypercalcemics, with exception of the carri-
ers of the polymorphism Arg990Gly) the normalization
of parathyroid hormone induced by cinacalcet, used in
combination with a diet with normalized calcium intake,
allows to control the "primary cause" of the renal stone
complication and thus achieve, as long as you continue
therapy, a concrete clinical advantage in terms of reduc-
tion in the number and size of stones, similarly to what
can be definitely achieved, with greater certainty, by sur-
gical parathyroidectomy that is definitely associated with
a significant risk reduction of calcium stones,frequent
remission or reduction of relapses (27, 28).
REFERENCES
1. Marangella M, Vitale C. Iperparatiroidismo primitivo e nefroliti-
asi: vi è spazio per i calciomimetici? GTN&D 2009;. 1:25-29.
2. Amaral LM, Queiroz DC, Marques TF, et al. Normocalcemic ver-
sus Hypercalcemic Primary Hyperparathyroidism: More Stone than
Bone? Journal of Osteoporosis 2012, Article ID 128352, 4 pages. 
3. Natalie E. Cusano, Shonni J. Silverberg, and John P. Bilezikian.
Normocalcemic Primary Hyperparathyroidism. Journal of Clinical
Densitometry: Assessment of Skeletal Health. 2013; 16:33e39.
4. Silverberg SJ, Bilezikian JP. Evaluation and management of primary
hyperparathyroidism. J Clin Endocrinol Metab. 1996; 81:2036. 
5. Parks J, Coe F, Favus M. Hyperparathyroidism in nephrolithia-
sis. Arch Intern Med. 1980; 140:1479.
6. Gesek FA, Friedman PA. On the mechanism of parathyroid hor-
mone stimulation of calcium uptake by mouse distal convoluted
tubule cells. J Clin Invest. 1992; 90:749.
7. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyper-
parathyroidism: new concepts in clinical, densitometric and bio-
chemical features. J Intern Med. 2005; 257:6.
8. Silverberg SJ, Shane E, Jacobs TP, et al. Nephrolithiasis and bone
involvement in primary hyperparathyroidism. Am J Med. 1990;
89:327.
9. Ghada El-Hajj Fuleihan, Shonni J Silverberg, Clifford J Rosen,
Jean E Mulder. Clinical manifestations of primary hyperparathy-
roidism. www.uptodate.com. 2014 UpToDate
10. Bilezikian JP, Khan AA, Potts JT Jr. Guidelines for the manage-
ment of asymptomatic primary hyperparathyroidism: summary
statement from the third international workshop. Third
International Workshop on the Management of Asymptomatic
Primary Hyperthyroidism. J Clin Endocrinol Metab. 2009; 94:335.
11. Shonni J Silverberg, Ghada El-Hajj Fuleihan, Clifford J Rosen,
Jean E Mulder. Management of primary hyperparathyroidism.
www.uptodate.com. 2014 UpToDate.
12. Bilezikian JP, Khan AA, Potts JT Jr. 2009 Guidelines for the
management of asymptomatic primary hyperparathyroidism: sum-
mary statement from the third international workshop. J Clin
Endocrinol Metab. 94:335-339.
13. Khan A, Grey A, Shoback D. Medical management of asympto-
matic primary hyperparathyroidism: proceedings of the third inter-
national workshop. J Clin Endocrinol Metab. 2009; 94:373.
14. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet
Correspondence
Simone Brardi, MD - sibrardi@gmail.com
Hemodialysis Unit, S. Donato Hospital, Arezzo, Italy
Gabriele Cevenini, MD - cevenini@unisi.it
Department of Surgery and Bioengineering, University of Siena, Siena, Italy                                  
Tiziano Verdacchi, MD - tiziano.verdacchi@usl8.toscana.it
Extracorporeal Shock Wave Lithotripsy Unit, S. Donato Hospital, Arezzo, Italy
Giuseppe Romano, MD - giuseppe.romano@usl8.toscana.it
Urology Unit, S. Maria della Gruccia Hospital, Montevarchi, Italy
Roberto Ponchietti, MD - ponchietti@unisi.it
Postgraduate Nephrology School, University of Siena, Siena, Italy
